Trials / Completed
CompletedNCT02921113
suPAR in the Early Diagnosis of Acute Kidney Injury(AKI) After On-Pump Cardiac Surgery
Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Early Diagnosis of Acute Kidney Injury After On-Pump Cardiac Surgery
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 105 (actual)
- Sponsor
- Marmara University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Acute Kidney Injury(AKI) is of the serious complications in patients with undergoing on-pump cardiac surgery. End stage kidney failure requiring dialysis therapy after cardiac surgery is associated with more than 60% mortality rate. Involvement of AKI after on-pump cardiac surgery increases the mortality rate 19 times. suPAR is one of the novel biomarker which has potential prognostic value for renal dysfunction in patients with undergoing on-pump cardiac surgery. Early diagnosis and prompt intervention to prevent AKI has great importance for management of postoperative cardiac patients.
Conditions
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2017-04-01
- Completion
- 2017-05-01
- First posted
- 2016-09-30
- Last updated
- 2017-09-08
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT02921113. Inclusion in this directory is not an endorsement.